AETIONOMY Clinical study recruitment finished with 411 patients recruited
AETIONOMY an IMI funded project, has now recruited 411 people into the Alzheimer’s (AD) and Parkinson’s Disease (PD) portion of the European clinical study on neurodegenerative diseases. Further Alzheimer’s disease samples will be taken from other successful clinical studies. This milestone means that the project finished recruitment and the patient bio samples will be now analyzed for disease specific biomarkers to validate mechanistic hypotheses for both diseases, stages and stratified patient subgroups.
Within the project, patients with neurodegenerative diseases and healthy people are providing blood and cerebrospinal samples to undergo detailed molecular analysis at leading European laboratories. The purpose of AETIONOMY is to propose novel patient classification based on mechanism-based taxonomies, for both PD and AD. ‘The AETIONOMY study will allow us to validate in real patients at least two hypotheses for PD and for AD,’ explains the study coordinator Prof. Jean Christophe Corvol of ICM, Paris. ‘This will then allow clinicians to stratify patients according to biological mechanisms of the disease and potentially to target specific sub-population for drug development.’
We are looking forward to propose new taxonomies for the Alzheimer’s and Parkinson’s Diseases on our Final Symposium on 29th/30th November 2018 in Bonn (D).